王旭先生自 2024 年 6 月起擔(dān)任本公司董事兼首席執(zhí)行官。王先生畢業(yè)于復(fù)旦大學(xué)微生物學(xué)系，獲理學(xué)碩士學(xué)位，在多家全球領(lǐng)先的制藥企業(yè)（包括葛蘭素史克和武田制藥）擁有超過二十年的高級管理及運營經(jīng)驗。自 2021 年起，王先生擔(dān)任廈門萬泰滄海生物科技有限公司總經(jīng)理，在提升 HPV 疫苗生產(chǎn)能力方面發(fā)揮了關(guān)鍵作用。在此之前，王先生于 2012 年至 2020 年在武田制藥任職，負責(zé)在中國廣州和德國辛根商業(yè)規(guī)模的生產(chǎn)和供應(yīng)鏈基地。2001 年至 2012 年，王先生在上海 GSK Biologics 工作，積累了豐富的國際疫苗行業(yè)經(jīng)驗。此外，王先生被認定為福建省高層次引進人才，并曾擔(dān)任國家藥品監(jiān)督管理局（NMPA）藥品生產(chǎn)質(zhì)量管理規(guī)范（GMP）培訓(xùn)講師。

Director

Mr. Xu Wang has served as our director, Chief Executive Officer since June 2024. Mr. Wang has graduated from FUDAN university and obtained the Master of Science degree. He has over twenty years of senior management and strong operational experience from a number of major Pharmaceutical manufacturers, including GSK, Takeda, and others. Mr. Wang has served as the general manager at Xiamen Innovax Co., Ltd. since 2021, where enhancing HPV vaccine production capacity. Prior to that, Mr. Wang worked at Takeda Pharmaceuticals from 2012 to 2020, where he was leading commercial-scale facilities in Guangzhou China and Singen Germany. From 2001 to 2012, Mr. Wang worked at Shanghai GSK Biologics. Mr. Wang was recognized as a Fujian Province Class A Talent and was an NMPA GMP Instructor.